Why the study?
Changes in myosin expression affect cancer cell migration, infiltrate formation, and metastasis, suggesting class I myosins may serve as markers or therapeutic targets.
Class I myosins are proposed as potential diagnostic, prognostic, or therapeutic targets in leukemia and other cancers due to their role in cell migration and metastasis.
Myosin changes merit exploration as leukemia biomarkers; leaves open clinical utility pending prospective validation.
Class I Myosins are a subfamily of motor proteins with ATPase activity and a characteristic structure conserved in all myosins: A N-Terminal Motor Domain, a central Neck and a C terminal Tail domain. Humans have eight genes for these myosins. Class I Myosins have different functions: regulate membrane tension, participate in endocytosis, exocytosis, intracellular trafficking and cell migration. Cell migration is influenced by many cellular components including motor proteins, like myosins. Recently has been reported that changes in myosin expression have an impact on the migration of cancer cells, the formation of infiltrates and metastasis. We propose that class I myosins might be potential markers for future diagnostic, prognostic or even as therapeutic targets in leukemia and other cancers.Abbreviations: Myo1g: Myosin 1g; ALL: Acute Lymphoblastic Leukemia, TH1: Tail Homology 1; TH2: Tail Homology 2; TH3: Tail Homology 3.
No takes yet. Share an insight, caveat, or question.
Díaz‐Valencia et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: